{"id":"W2160719528","doi":"10.1200/jco.2009.24.0143","title":"Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Clinical Oncology Group; University of Toronto; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Cyclophosphamide; Internal medicine; Metastatic breast cancer; Prednisone; Vascular endothelial growth factor; Chemotherapy; Gastroenterology; Clinical endpoint; Breast cancer; Phases of clinical research; Oncology; Progressive disease; Methotrexate; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001346503,0.001710701,0.002129052,0.0004845195,0.0004450385,0.0007681279,0.000913794,0.001370199,0.002565262],"category_scores_gemma":[0.0008994811,0.0005623585,0.0006974739,0.0004487309,0.00136396,0.000649224,0.0003279865,0.002239611,0.0005722669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008220107,"about_ca_system_score_gemma":0.001256497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005123263,"about_ca_topic_score_gemma":0.001129314,"domain_scores_codex":[0.999534,0.0002475652,0.00002340011,0.00007865718,0.00003621224,0.00008026318],"domain_scores_gemma":[0.99911,0.0001162617,0.0001986308,0.00007362591,0.00003597876,0.0004653705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8382556,0.05488527,0.005691554,0.0004937472,0.0005758354,0.0001896363,0.0001915769,0.002302931,0.03154421,0.0004656915,0.002758878,0.06264507],"study_design_scores_gemma":[0.6520228,0.3366831,0.004446286,0.00002261437,0.0001864446,0.0001968564,0.00003251877,0.001285137,0.003137211,0.0002024042,0.00176804,0.00001637319],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875723,0.00216161,0.0009104811,0.0006691216,0.0002083886,0.005490791,0.0006734966,0.0001589179,0.002154833],"genre_scores_gemma":[0.9809743,0.001309563,0.003077476,0.001399393,0.0002631544,0.008090352,0.001785829,0.00002966473,0.003070246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002565262,"threshold_uncertainty_score":0.008581638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08840411151474677,"score_gpt":0.4399860116120404,"score_spread":0.3515819000972936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}